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Abstract
Background: Gastric cancer remains a major cause of mortality and morbidity worldwide. In recent years, gene-based
therapeutic strategies were confirmed promising in cancer inhibition and attracted great attention. RNA interference
(RNAi) is a powerful tool for gene therapy and has been widely employed to aid in treatment for various diseases,
especially cancers. However, effective delivery of small interfering RNA (siRNA) to target cells in vivo remains a
challenge for that it is prone to degradation and only lasts a few days in rapidly dividing cells.
Methods: Due to its biocompatibility and well-established safety profile, collagen represents a favourable matrix
for in-site drug delivery. In the study, collagen hydrogel was used as carriers to test the feasibility of localized and
sustained delivery of Id1-targeted siRNA for in vivo gastric cancer inhibition. To enhance the siRNA delivery, cationic
polyethylenimine (PEI) was further emplored for scallold modification. The efficacy of siRNA delivery and cancer
inhibition were evaluated with multimodality of mehods in vitro and in vivo.
Results: Our results showed that addition of polyethylenimine (PEI) to collagen can facilitate entry of Id1-siRNA
into target cells, prolong the silencing effect, and further inhibit tumor growth both in vitro and in vivo.
Conclusion: This collagen-based delivery system may facilitate the pathogenesis elucidation and design of effective
therapies against gastric cancer.
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Background
RNA interference (RNAi) is a post-transcriptional gene
silencing tool that can inhibit the expression of target
gene by causing degradation of the specific mRNA
molecule. As a new technology, it is widely used in
functional research on cancer genes as well as thera-
peutics for a variety of tumors [1]. In gastric cancer,
several genes have been proved to be closed related to
proliferation and migration of gastric cancer cells, such
as Stathmin1, Id1, PLCE1. These genes have been shown
to be important targets for gastric cancer therapy for the
fact that silencing of them by RNAi significantly inhibits
proliferation and migration of gastric cancer cells [2–4].
However, effective delivery of small interfering RNA
(siRNA) to target cells in vivo is far from realizing its full
therapeutic potential because it is prone to degradation by
RNases [5], the silencing effect only lasts a few days in
rapidly dividing cells [6], and retention of the siRNA at a
specific location is difficult [7].
Lentiviral transfection was effective to deliver siRNA
into target cells, but safty will be a major concern when
considerred in vivo application. No-viral biomaterial
vectors should be more rational option for in vivo
siRNA delivery. In fact, several biomaterials have been
investigated as scaffold for in vivo delivery of therapectic
agents, such as carbon nanotubes and chitosan [8, 9]. As
a major natural constituent tissue and a major structural
protein of any organ, collagen is of particular interest as
a biomaterial in drug delivery system. Biomaterials made
of collagen possess the advantages of biocompatibility,
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non-toxicity, and well-documented properties [10]. Col-
lagen has been shown to retain siRNA locally and re-
lease it in a sustained manner to prolong the effect
directly at the specific site by Krebs and his colleagues
[11]. Through this delivery system, novel candidates can
be tested for effective therapies against gastric cancer
before further clinical application. In addition, charac-
teristics of this strategy for interference and therapeu-
tics on gastric cancer, both in vitro and in vivo, needs
to be demonstrated.
In this study, we mainly investigated the feasibility
of localized and sustained delivery of Id1-targeted
siRNA incorporated within collagen, the characteristic
of siRNA release profile, and its effect on growth and
migration ability of gastric cancer cells both in vitro
and in vivo.
Methods
All the experiments in the study were approved by the
ethics committee of Beijing Meitan General Hospital
(China).
Cell culture
The SGC-7901 gastric cancer cell line was purchased from
ATCC and cultured in high-glucose DMEM (Gibco, BRL,
Beijing, China) supplemented with 10 % fetal bovine
serum at 37 °Cwith 5 % CO2.
Id1 small interfering RNA (siRNA)
Id1-specific siRNA used for Id1 knockdown and the
control siRNA were synthesized by Invitrogen (Beijing
Invitrogen Co., Ltd.). The sequences of siRNA targeting
the Id1 coding region were as follows: sense, 5’-CUCGG
AAUCCGAAGUUGGADTDT-3’ and antisense, 5’-UCC
AACUUCGGA UUCCGAGDTDT-3’. The siRNAs were
transfected into cells by Lipofectine 2000 (Invitrogen,
USA), according to the manufacturer’s instructions.
MTT assay
Briefly, cells were trypsinized and seeded into 96-well
plates at a density of 5 × 103 cells/well in a volume of
150 μl. The cells were incubated with 20 μl, 5 mg/ml of
MTT (Sigma-Aldrich, St. Lousis, MO, USA) solution for
4 h under regular culture condition. After the super-
natant was removed, 150 μl DMSO was added to dis-
solve the crystals. The absorbance values at 570 nm
were read at specified time points with a BioTek Synergy
2 multiwell spectrophotometer. Viable cells were tested
at 0, 1, 2, 3 days after plating, and each experiment was
repeated three times.
PureCol collagen (97 % type I collagen) was obtained
from Inamed Biomaterials (Fremont, CA). Polyethyleni-
mine (PEI) “Max” was obtained from Polysciences, Inc.
(Warrington, PA). The RiboGreen RNA quantitation
reagent was obtained from Invitrogen (Carlsbad, CA).
Release and bioactivity of siRNA from hydrogels
Hydrogels containing 15 μg (10 μl) siRNA were fabri-
cated in transwell membranes with 0.4 μm pore-size.
The siRNA was mixed into 90 μl of 3 mg/ml collagen
solutions. The collagen solution was kept on ice during
this process. For collagen mixed with PEI, PEI was
mixed with siRNA to form a final concentration of
0.2 mg/ml at room temperature for 20 mins . Then the
mixture was added into the same amount of collagen
solution and pipetted onto transwell membranes. The
collagen solution was placed into a 37 °C incubator for
45 min to allow hydrogel formation. For release studies,
the transwell membranes were placed into the wells of a
24-well plate containing PBS, the PBS was replaced at
various time points, and the siRNA content in each
sample was measured using the RiboGreen RNA quanti-
tation reagent.
Transfection of cells incorporated within hydrogels
The SGC-7901 gastric cancer cells were mixed within
the collagen solution at a density of 5 × 105 cells/ml. The
hydrogels on the transwell membranes were cultured in
the presence of accell delivery media (ADM), which was
replaced with ADM supplemented with 1 % FBS on days
1, 3, and 5. The cells within the hydrogels were trypsi-
nized by type I collagenase and the DNA content was
measured by Quant-iT™ PicoGreen Kit (Invitrogen).
RT-PCR and western blotting
Total RNA from cultured cells was extracted and then
reverse transcribed using commercial kits from Tiangen
(Beijing, China). Then, 2 μl of cDNA was used for the
quantitative polymerase chain reaction (qPCR) using
SYBR Green Realtime PCR Master Mix (TOYOBO,
Osaka, Japan) in Eppendorf Mastercycler Realplex Real-
time PCR system. GAPDH was used for normalization
of mRNA. Cells ere collected and treated with RIPA
lysis buffer. Lysate with 60 μg protein was separated
by 15 % sodium dodecyl sulphate-polyacrylamide gel
electrophoresis. After electrophoresis, proteins were
transferred onto a polyvinylidene difluoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA) and blocked with
5 % milk. Then the membrane was incubated with
anti-cyclin D1, p16, p-Akt, Akt and GAPDH anti-
bodies (Cell Signaling Technology) overnight at 4 °C,
followed by washing and incubation with a horseradish
peroxidase-conjugated secondary antibody (Santa Cruz
Biotechnology). The membrane was washed and detected
by enhanced chemiluminescence with Millipore reagents.
The expression level of the target protein was normalized
to GAPDH by a scan software.
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Studies of gastric cancer xenograft tumor models in
nude nice
Six-week-old male BALB/c nude mice were purchased
from laboratory animal center of Academy of Military
Medical Sciences and housed in a temperature-controlled,
pathogen-free animal facility with 12-h light and dark cy-
cles. 2 × 106 gastric cancer cells were mixed with DMEM
solution, siRNA solution, siRNA solution within collagen,
siRNA solution within collagen and PEI, respectively and
then injected hypodermically into the nude mice. After
4 weeks, the tumors were collected and weighted.
Immunocytochemistry
Expression of cyclin D1, P21 and PCNA in tumor cells
were identified by immunostaining with a polyclonal
rabbit anti-rodent antibodies. Diamino-benzidine and
alkaline phosphatase substance (ZhongShan Goldenbridge
biotech, Beijing, China) were used to visualize the proteins.
Statistical analysis
Data were expressed as the means ± SD. Statistical ana-
lyses were performed using Student’s t-test. P < 0.05 indi-
cated statistical significance.
Results
Effects of Id1 siRNA or pcDNA3.1-Id1 on cell cycle-related
protein expression and SGC-7901 cell proliferation
The effects of siRNA or pcDNA3.1-Id1 on the levels of
Id1, cyclin D1, p16, p21 were evaluated using reverse
transcriptase-PCR. As shown in Fig. 1a, the target gene
expression decreased with the dose of Id1 siRNA. When
the concentration of Id1 siRNA reached 0.5 μm or more,
the maximal inhibition of target gene Id1 in SGC-7901
cells was achieved. Therefore, 1 μm concentration of Id1
siRNA was chosen for the following experiments. Then,
we detected the expression of Cell Cycle genes. As
shown in Fig. 1b, cyclin D1 mRNA was found to be de-
creased due to the silencing of Id1, while p16 and p21
expression were increased in the siRNA tranfected cells.
The results suggested that cell proliferation may be
inhibited. To evaluate the effect of Id1 on the prolifera-
tion of SGC-7901 cells, MTT assay was performed. As
shown in Fig. 1c, proliferation of SGC-7901 cells was
inhibited by Id1 interference and the effect was evident
after 72 h transfection with Id1 siRNA.
Cumulative release of siRNA from hydrogels
To measure the release of siRNA molecules from colla-
gen hydrogels, the same amount of siRNA was incorpo-
rated into collagen or collagen with PEI, release from
two systems was quantified over a period of 10 days. As
shown in Fig. 2, siRNA was released in a sustained man-
ner for about 2 weeks from collagen. And the addition
of PEI to collagen delayed the release of siRNA into the
surrounding media. These results suggested that siRNAs
were effectively retained within the hydrogels, which
may decrease their loss and enhance their efficacy to
surrounding cells.
Fig. 1 Concentration optimization of siRNA for efficient interference on target gene. a. RT-PCR analysis showed that Id1 expression can be
suppressed by siRNA in a dose-dependent manner. 1 μM concentration of siRNA was used in the followed assays for sufficient interference
effect. b. Effects on the cell cycle-related genes through downregulation of Id1. c. MTT assay was performed indicating that Id1-siRNA showed
remarkable inhibitory effects on the proliferation of SGC-7901 cells
Peng et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:57 Page 3 of 9
Target gene inhibition by siRNA
lipofectamine 2000 was used as control for comparison.
As shown in Fig. 3, the maximal inhibition of target gene
through lipofectamine 2000 was achieved at 2 days after
tranfection and then, the inhibited Id1 expression grad-
ually recoverred. The inhibitory effect through lipofec-
tamine 2000 tranfection only lasted less than one week;
while those for siRNA incoporated into collagen lasted
for 2 weeks. The maximal inhibition of target gene was
achieved at 4–8days, and the inhibiton was more potent
than tha by lipofectamine 2000 tranfection. The addition
of PEI into collagen further prolonged the inhibitory
effect, which may indicate that PEI delayed the release of
siRNA into the surrounding media. Meanwhile, the could
exclude the degradation or inactivation of siRNA within
the complex.
Measurement of tumor cell DNA content and cell
proliferation analysis
To determine cell proliferation, DNA content was mea-
sured to quantify the cell numbers. As shown in Fig. 4,
the DNA content from cells exposed to siRNA/collagen
and siRNA/collagen/PEI was significantly lower that of
the control group both at day 7 and day 14, indicating
that tumor cell proliferation was inhibited.
Western blotting and expression level changes of cell
cycle-related genes from different groups
The changes of certain cell cycle regulators were ana-
lyzed through western blotting. As shown in Fig. 5, The
expression levels of cyclin D1 and p-Akt were decreased
significantly in cells exposed to siRNA in the hydrogels
compared comtrol, while p16 was increased, which was
consistent with previous studies [12]. Further, the addition
of PEI strengthens this effect.
Inhibitory effect on tumor growth in vivo
Four weeks after transplantation, tumors were collected
and their weights were measured. As shown in Fig. 6,
the tumor volums were obviously smaller in siRNA/
collagen and siRNA/collagen/PEI groups compared with
control group. Weighing of tumors also demonstrated
that tumor weight from siRNA/collagen and siRNA/
collagen/PEI treated nude mice were significantly lower
than that from the control group, which showed that
collagen-mediated delivery of siRNA inhibits tumor growth
in vivo.
Immunostaining of cyclin D1 and P21 in tumor cells
To determine the effects of siRNA transfection on the
cell cycles within tumors, paraffin-embeded sections were
prapared and immunostained with cell cycle-related anti-
bodies. As shown in Fig. 7, significantly less cells were
stainned positive by anti-cyclin D1 antibodies in the
Fig. 2 Cumulative release of siRNA from hydrogels. Collagen with or
without the addition of PEI to modulate siRNA release
Fig. 3 Different release profiles of siRNA under different conditions.
Cells were exposed to no siRNA, siRNA only in the hydrogels, siRNA
present in the media, or siRNA in hydrogels with the addition of PEI.
RT-PCR analysis was performed. Values are the means ± SD of 3
wells. Id1 mRNA levels in the treated-cells were normalized to the
control group cells
Fig. 4 Cell proliferation analysis through measuring DNA content
from tumor cells. Cells were exposed to no siRNA, siRNA only in
the hydrogels, or siRNA in hydrogels with the addition of PEI and
DNA content was measured
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siRNA/collagen treated tumor cells, suggesting that
cyclin D1 was significantly downregulated; while P21
expression was significantly increased, indicating that
the cell cycle was inhibited. The inhibitory effect from
the siRNA/PEI/collagen group was more evident.
Immunohistochemical analysis of PCNA expression in
tumors from different groups
PCNA was an important marker of cell proliferation. In
addition, its expression has also been suggested to have
prognostic significance for gastric cancer [13]. To deter-
mine the cell proliferation within tumors, we further per-
formed immunostaining on tumor sections with PCNA
antibodies. As shown in Fig. 8, the positive immunostaining
rate of PCNA for siRNA/collagen group and siRNA/PEI/
collagen group was significantly lower than that of the
control group and siRNA/Medium group, indicating cell
proliferation was significant inhibited. In comparison, the
inhibitory effect on cell proliferation from the siRNA/PEI/
collagen group was the most evident.
Discussion
RNA interference (RNAi) is a biological process in
which introduction of double-stranded RNA (dsRNA)
into cells can effectively and specifically lead to the deg-
radation of corresponding mRNAs [14]. This powerful
tool has been widely employed to identify gene func-
tions, elucidate signal pathways, and aid in treatment for
various diseases, especially in cancers. However, effective
delivery of small interfering RNA (siRNA) to target cells
in vivo remains a challenge for that it is prone to deg-
radation and the silencing effect only lasts a few days in
rapidly dividing cells. Thus, methods for localized and
sustained delivery of silencing RNA into cells need ex-
ploring. In the present study, we first employed collagen
hydrogel as carriers for in vivo delivery of siRNA into
gastric tumors. We demonstrated that siRNA could be
effectively retained within the hydrogel due to its in situ
gelation property. More importantly, the incorporated
siRNAs could be of delayed release, which significantly
prolonged their action time and enhanced their efficacy
on target gene. Consequently, a potent inhibition of gas-
tric tumors was achieved in vivo through collagen-based
siRNA delivery. The findings and methods of the study
may indicate a promising strategy for gene therapy of
cancers in future.
Current approaches for delivery of siRNA into target
cells include viral-based transfection, incorporation into
Fig. 5 The expression level changes of cell cycle-related genes from different groups. Western blot analysis of the expression levels of cyclin D1,
p16 and p-Akt. The expression of the target proteins were expressed as relative levels to GAPDH
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liposomes, chemical conjugation with molecules to facili-
tate targeting, complexation with positively charged pep-
tides or polymeric nano- or microspheres [15]. Generally,
these methods could be divided into two categories: viral
method and non-viral method. A typical viral method for
siRNA delivery should be lentiviral transfection, which
was a lentivirus-based method to deliver siRNA into target
cell. In past years, lentiviral transfection of siRNA was
widely used and for many types of cells, it was effective for
siRNA delivery. However, lentiviral transfection was com-
panied with potential safety concerns, such as insertional
mutagenesis and aberrant splicing [16, 17]. These were
important reasons why non-viral methods were exten-
sively investigated. In the field of non-viral siRNA delivery,
Fig. 6 Inhibitory effect on tumor growth in vivo. Macroscopic images of the tumors from nude mice and tumor weight from different groups
Fig. 7 Immunostaining of cyclin D1 and P21 in tumor cells. cyclin D1 expression was downregulated in the siRNA/collagen treated tumor cells,
while P21 expression was significantly increased, indicating that the cell cycle was inhibited. The inhibitory effect from the siRNA/PEI/collagen
group was more evident. (scale bars, 100 μm)
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most methods were based on compatible biomaterial vec-
tors. Collagen is a native extracellular matrix molecule
which can serve as physical support to promote tissue
organization and scar tissue formation [18, 19]. It has been
demonstrated by different groups that collagen hydrogel
were favourable vectors, that they have the potential to de-
liver various bio-agents, such as cytokines [20], living cells
[21, 22], as well as exogenous microRNAs [23]. One
strong advantage of this hydrogel as biopolymer scaffolds
is that it is injectable and delivery to the site of interest is
minimally invasive. Also, its hydrophilic nature and high
gas permeability permits easy transport of nutrients and
oxygen and removal of waste products. Thus this injectable
biopolymer-based siRNA delivery system may have great
utility in therapeutic medicine.
Different from certain Western European countries
and the United States, gastric carcinoma is a common
disease with high incidence rates in several Asian coun-
tries, particularly in Japan and China [24, 25], and the 5-
year survival rate is low due to the majority of the cases
being detected at advanced stages [26]. Finding new tar-
gets to improve therapeutic or preventive strategies is
important. Inhibitor of DNA binding 1 (Id1) is a mem-
ber of the helix-loop-helix transcription factor family
that is overexpressed in various types of cancer, includ-
ing gastric carcinoma [27]. Previous studies showed that
Fig. 8 Immunohistochemical analysis of PCNA expression intumors from different groups. The expression rate from siRNA/collagen group and
siRNA/PEI/collagen group was significantly lower than that from control group and siRNA/Medium group. And the inhibitory effect on cell proliferation
from the siRNA/PEI/collagen group was the most evident. **P< 0.01 compared with control group; ## P< 0.01 compared siRNA/collagen group
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Id1 is a prognostic marker in patients with gastric cancer
which is involved in the growth and migration of gastric
cancer cells [28, 29]. Certain reports have suggested that
Id1 can regulate various cell processes, including prolif-
eration, apoptosis, cell cycle, differentiation and angio-
genesis [3, 30, 31]. Further research have showed that
down-regulation of Id1 by small interfering RNA in gas-
tric cancer inhibits cell growth via the Akt pathway [32].
Thus, Id1 may be an important target for gastric cancer
therapy. In the study, we chose Id1 as target gene aiming
to investigate the inhibitory efficacy of collagen-based in
vivo siRNA delivery on gastric cancer. We confirmed
that this delivery system was effective for in vivo gene si-
lencing. In addition to Id1 gene, several other genes have
also been confirmed to be related to the proliferation,
migration and survival of gastric cancer cells, such as
Class I phosphoinositide 3-kinase, stathmin1, PLCɛ1
[2, 33, 34], and so on. Though other genes were not
tried in the study, we believed that the delivery system
should be equally effective for other genes. Actually, in
an in vitro study by Krebs and colleagues [11], the de-
livery system was confirmed effective too with another
target gene.
Conclusions
In this study, we mainly investigated the feasibility of
localized and sustained delivery of Id1-targeted siRNA
which has been incorporated into collagen and its effect
on the growth and migration ability of gastric cancer
cells both in vitro. Results showed that the release pro-
file of siRNA incoporated into collagen was significantly
prolonged. And the addition of polyethylenimine (PEI)
to collagen can facilitate the entry of siRNA into target
cells which further prolong the silencing effect of siRNA.
Also this collagen-based delivery system exhibits evident
inhibitory effect on tumor growth in vivo, which may be
further utilized for interference and therapeutics on gastric
cancer cells.
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